,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
updates from #db03 by : no new safety signal. ae in light of exposure (exposure adjusted ae) is important to consider given difference in treatment duration between t-dm1 and t-dxd #asco22 
#BreastCancer Chief Oncologist | Researcher | Executive Medical Director @BCMCancerCenter @StLukesHealthTX | Innovation | Access to care | Views are my own